Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Cyteir Therapeutics revenue
Cyteir Therapeutics's revenue is $1.6 million.
What is Cyteir Therapeutics's revenue?
- Cyteir Therapeutics has 26 employees, and the revenue per employee ratio is $60,267.
- Cyteir Therapeutics peak revenue was $1.6M in 2024.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Cyteir Therapeutics financing
Cyteir Therapeutics received early financing of $5.5M on 2015-11-05.
| Series | Round size | Date |
|---|---|---|
| Series A | $5.5M | 11/2015 |
| Grant | $2M | 06/2016 |
| Series B | $29M | 03/2018 |
| Series B | $40.2M | 10/2019 |
| Series C | $80M | 02/2021 |
Cyteir Therapeutics investors
| Investors | Security type |
|---|---|
| Celgene Corporation | Series A |
| National Institutes of Health (NIH) | Grant |
| Celgene Corporation | Series B |
| Lightstone Ventures | Series B |
| DROIA Ventures | Series B |
| Osage Partners | Series B |
| Venrock | Series B |
| Novo Holdings A | Series B |
| Celgene Corporation | Series B |
| Lightstone Ventures | Series B |
| DROIA Ventures | Series B |
| Osage Partners | Series B |
| Venrock | Series B |
| Ally Bridge Group | Series C |
| Novo Holdings A | Series C |
| Avidity Partners | Series C |
| Lightstone Ventures | Series C |
| Osage Partners | Series C |
| DROIA Ventures | Series C |
| Acuta Capital Partners | Series C |
| Venrock | Series C |
| Janus Henderson Investors | Series C |
| RA Capital Management | Series C |
| CaaS Capital Management | Series C |
| Ample Plus Fund | Series C |
Cyteir Therapeutics competitors
Cyteir Therapeutics's top competitor, Arvinas Inc., earned an annual revenue of $263.4M.
Cyteir Therapeutics's smallest competitor is Obsidian Therapeutics with revenue of $1.5M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Tango Therapeutics | - | $42.1M | 91 | - |
| Salarius Pharmaceuticals | - | $5.2M | 5 | - |
| Mateon Therapeutics | - | $5.6M | 13 | - |
| IDEAYA Biosciences | - | $7.0M | 69 | - |
| Nurix | - | $54.5M | 103 | - |
| Pharmacyclics | - | $235.0M | 607 | - |
| Arvinas Inc. | - | $263.4M | 83 | - |
| Lantern Pharma | - | $1.5M | 11 | - |
| Surface Oncology | - | $30.0M | 51 | - |
| Cabaletta Bio | - | $1.6M | 20 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Cyteir Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Cyteir Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Cyteir Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Cyteir Therapeutics. The data presented on this page does not represent the view of Cyteir Therapeutics and its employees or that of Zippia.
Cyteir Therapeutics may also be known as or be related to CYTEIR THERAPEUTICS, INC., Cyteir Therapeutics, Cyteir Therapeutics Inc and Cyteir Therapeutics, Inc.